Mizuho Securities analyst Uy Ear has maintained their bullish stance on ALKS stock, giving a Buy rating on September 26. Uy Ear has given his ...

Last week, Bristol Myers BMY obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo ...

Anavex faces challenges with failed drug trials, operational risks, and questionable decisions, leading to a strong sell ...

The recent FDA approval of KarXT (Cobenfy), developed by Karuna Therapeutics (a subsidiary of Bristol Myers Squibb), marks a ...

Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...

Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...

Schizoid personality disorder can include constant daydreaming, but unlike schizophrenia, the daydreaming of schizoid personality disorder does not include hallucinations or a complete disconnect with ...

Millions of Americans are living in a world that doesn't exist. They hear voices, see things others can't, and hold beliefs ...

Scientists now have greater insight into one of Schizophrenia's poorly understood hallmarks — auditory hallucinations.

FARGO — A new FDA approved drug, to help people with schizophrenia, will soon be accessible for medical officials to ...